Opsona News

Opsona presents preliminary results at 58th Annual ASH Meeting

Seroba’s investee company, Opsona Therapeutics Ltd (‘Opsona’), the innate immune drug development company focused on novel therapeutic approaches to treat oncology, autoimmune and other inflammatory diseases, today announced that it will present preliminary results from its ongoing prospective, open label Phase I/II study being conducted with OPN-305 in second-line lower (Low and intermediate-1) risk myelodysplastic syndrome (MDS).

The presentation will take place on Saturday, 3 December at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego.

Myelodysplastic syndromes are a complex and heterogeneous group of bone marrow failure disorders characterized by ineffective hematopoiesis and poor prognosis. There is an urgent need for the development of novel therapies in the treatment of MDS which can delay progression, improve patient survival and quality of life, and which have fewer adverse effects. Opsona has recently received orphan drug designation (ODD) from the United States Food and Drug Administration for MDS.

OPN-305 is a novel proprietary humanized IgG4 monoclonal antibody (MAb) against Toll-Like Receptor 2 (TLR2), a key target within the innate immune system.

The study in patients with lower risk MDS who have failed hypomethylating agents is ongoing in collaboration with MD Anderson Cancer Center in Houston USA with additional sites now being added in the USA. The lead principal investigator Professor Guillermo Garcia-Manero will present the preliminary data at ASH and commenting on today’s announcement said “Inhibition of TLR2 with OPN-305 is safe and is currently demonstrating strong clinical activity in patients with lower risk MDS after hypomethylating agent therapy”

Details of the presentation are as follows:

A Clinical Study of OPN-305, a Toll-like receptor 2 (TLR-2) antibody, in patients with Lower Risk Myelodysplastic Syndromes (MDS) that have received prior Hypomethylating Agent (HMA) Therapy

Abstract # 227
Session Name: 637. Myelodysplastic Syndromes—Clinical Studies: Lower Risk MDS Clinical Studies
Session Date: Saturday, December 3, 2016
Session Time: 4:00 PM – 5:30 PM
Presentation Time: 5:00 PM
Room: Manchester Grand Hyatt San Diego, Grand Hall C

The ASH abstract is now online can be accessed here:

For further information, please contact:
Vicky La Touche-Price, Seroba Life Sciences, +353 1 6334028.

Recent Articles

Susan Trent Photo

Atlantic Therapeutics appoints Susan Trent as new CEO, based in the United States.

Galway, Ireland.   Seroba’s portfolio company, Atlantic Therapeutics, a Galway-based MedTech and Femtech innovator, announces a transition in leadership to fulfill […]

Read More
Cancer Killers

Fusion Pharmaceuticals Announces Pricing of Initial Public Offering.

HAMILTON, ONTARIO and Boston. 25 June 2020.  Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation […]

Read More
Alflorex Zenflore V2

Novozymes acquires PrecisionBiotics Group.

25 June 2020.  Seroba’s portfolio company, PrecisionBiotics Group has been acquired by Novozymes. Based in Cork, Ireland, PrecisionBiotics Group holds […]

Read More
The Big Taboo

New U.K. Study Offers Good News to Sufferers During World Continence Week

A new study has been published in the Journal of Medical Economics demonstrating that INNOVO® is a compelling and cost-effective […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19

Scroll to Top